Haemonetics Corporation 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the 2025 Annual Meeting of Shareholders held on July 24, 2025. Haemonetics Corporation is incorporated in Massachusetts and its common stock trades on the New York Stock Exchange under the symbol HAE.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting outcomes.
Material Changes and Voting Results
Of the 48,041,228 shares outstanding, 45,613,041 shares (94.95%) were represented at the meeting, constituting a quorum. The following proposals were voted upon:
- Election of Directors: Shareholders elected nine directors for one-year terms expiring in 2026. All nominees received significant "For" votes, with withhold votes ranging from approximately 99,000 to 1.27 million shares.
- Executive Compensation: The advisory vote on named executive officer compensation was approved with 43,016,961 votes "For" and 585,626 votes "Against."
- Auditor Ratification: Shareholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending March 28, 2026, with 43,843,396 votes "For" and 1,525,114 votes "Against."
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the specific terms and compensation packages for the newly elected board members.
- Review the full proxy statement for details on the executive compensation plan approved by shareholders.
- Confirm the scope of the audit engagement with Ernst & Young LLP for the fiscal year ending March 28, 2026.
- Monitor subsequent filings for the company's financial results for the period ending March 28, 2026.